NovMetaPharma (A229500) Stock Overview
Engages in the development and sale of drugs to treat metabolic diseases in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
A229500 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
NovMetaPharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩13,280.00 |
| 52 Week High | ₩13,300.00 |
| 52 Week Low | ₩4,505.00 |
| Beta | 0 |
| 1 Month Change | 33.47% |
| 3 Month Change | 72.47% |
| 1 Year Change | 121.33% |
| 3 Year Change | 10.67% |
| 5 Year Change | -65.28% |
| Change since IPO | 33.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| A229500 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 23.5% | 3.4% | -1.1% |
| 1Y | 121.3% | 5.1% | 11.2% |
Return vs Industry: A229500 exceeded the KR Pharmaceuticals industry which returned 5.1% over the past year.
Return vs Market: A229500 exceeded the KR Market which returned 11.2% over the past year.
Price Volatility
| A229500 volatility | |
|---|---|
| A229500 Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 4.4% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.4% |
| 10% least volatile stocks in KR Market | 2.8% |
Stable Share Price: A229500's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A229500's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Sun-Wook Hwang | www.novmeta.com |
NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic diseases in South Korea. The company is developing NovDB2, a type 2 diabetes medication; NovOB, an anti-obesity medication; NovRD, a chronic kidney disease medication; NovFS, a fibrosis medication; and NovRF, a retroperitoneal fibrosis medication. It also develops drugs for inflammatory bowel; viral; vascular; bone loss; bone loss; cognitive impairment; Alzheimer’s; acute pancreatitis; degenerative brain; and liver cancer diseases, as well as cytokine inhibitor and exercise performance enhancement products.
NovMetaPharma Co., Ltd. Fundamentals Summary
| A229500 fundamental statistics | |
|---|---|
| Market cap | ₩161.03b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
Is A229500 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A229500 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A229500 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/23 23:01 |
| End of Day Share Price | 2025/07/23 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NovMetaPharma Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.